Epothilones in prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 4, 2011, Pages 358-365

  Kelly, William K ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Castration resistant prostate cancer; Chemotherapy; Epothilones; Ixabepilone; Resistance

Indexed keywords

ANTHRACYCLINE; BETA TUBULIN; CAPECITABINE; DOCETAXEL; EPOTHILONE B; ESTRAMUSTINE; GLYCOPROTEIN P; IXABEPILONE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SAGOPILONE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LIMB PAIN; MICROTUBULE ASSEMBLY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOSIS; TUMOR RESISTANCE; TUMOR VOLUME; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 79959869773     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.08.005     Document Type: Review

References (53)

1. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371:1710-1721.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
3. Clinical Guidelines. Guideline for the management of clinically localized prostate cancer American Urological Association, Revised 2007. Accessed July 29, 2009. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/proscan07/content.pdf.
4. D'Amico A.V., Manola J., Loffredo M., et al. Six-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004, 292:821-827.
5. Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
6. De Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int 2008, 101(Suppl 2):11-15.
7. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
8. Berry D.L., Moinpur C.M., et al. Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006, 24:2828-2835. Southwest Oncology Group.
9. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
10. Mathew P., Dipaola R. Taxane refractory prostate cancer. J Urol 2007, 178(3 Pt 2):S36-S41.
11. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
12. Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005, 204:216-237.
13. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. J Pathol 2005, 205:275-292.
14. Lee J.T., Steelman L.S., McCubrey J.A. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004, 64:8397-8404.
15. Hait W.N., Yang J.M. The individualization of cancer therapy: The unexpected role of p53. Trans Am Clin Climatol Assoc 2006, 117:85-101.
16. Lih C.J., Wei W., Cohen S.N. Txr1: A transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev 2006, 20:2082-2095.
17. McCubrey J.A., Steelman L.S., Abrams S.L., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46:249-279.
18. Yoshino T., Shiina H., Urakami S., et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006, 12(20 Pt 1):6116-6124.
19. Hari M., Loganzo F., Annable T., et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006, 5:270-278.
20. Lee F.Y., Smykla R., Johnston K., et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009, 63:201-212.
21. O'Reilly T., Wartmann M., Brueggen J., et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008, 62:1045-1054.
22. Sève P., Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol 2008, 9:168-175.
23. Hasegawa S., Miyoshi Y., Egawa C., et al. Prediction of response to docetaxel by quantitative analysis of class I and III β-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003, 9:2992-2997.
24. Burkhart C.A., Kavallaris M., Band Horwitz S. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001, 1471:1-9.
25. Lee FY, Wen M-L, Shen H, et al. Ixabepilone overcomes multiple mechanisms of drug resistance including overexpression of class III β-tubulin and breast cancer resistance protein. Poster presented the 6th European Breast Cancer Conference, Berlin, Germany, April, 2008.
26. IXEMPRA® Kit (Ixabepilone) for injection 2007, [package insert], Bristol-Myers Squibb Company, Princeton NJ.
27. Bollag D.M., McQueney P.A., Zhu J., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995, 55:2325-2333.
28. Nettles J.H., Li H., Cornett B., et al. The binding mode of epothilone A on α, β-tubulin by electron crystallography. Science 2004, 305:866-869.
29. Ranganathan S., Benetatos C.A., Colarusso P.J., et al. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998, 77:562-566.
30. Kamath K., Wilson L., Cabral F., et al. βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005, 280:12902-12907.
31. Mozzetti S., Ferlini C., Concolino P., et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005, 11:298-305.
32. Jordan M, Miller H, Ni L, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered β-tubulin expression and is sensitive to ixabepilone. Washington, DC: Proceedings of the 97th Annual Meeting of the American Association of Cancer Research April 2006;LB-280.
33. Kowalski R.J., Giannakakou P., Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem 1997, 272:2534-2541.
34. Altmann K.H., Wartmann M., O'Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000, 1470:M79-M91.
35. Fumoleau P., Coudert B., Isambert N., et al. Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007, 18(Suppl 5):v9-v15.
36. Harrison M., Swanton C. Epothilones and new analogies of the microtubule modulators in taxane-resistant disease. Expert Opin Investig Drugs 2008, 17:523-546.
37. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients. Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007, 110:556-563.
38. Lee J.J., Swain S.M. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005, 32:S22-S26.
39. Pivot X., Dufresne A., Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer 2007, 7:543-549.
40. Vahdat L. Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 2008, 13:214-221.
41. Wartmann M., Altmann K.H. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002, 2:123-148.
42. Smaletz O., Galsky M., Shor H.I., et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003, 14:1518-1524.
43. Galsky M.D., Small E.J., Oh W.K., et al. Multi-national randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005, 23:1439-1446.
44. Hussain M., Tangen C.M., Lara P.N., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: A Southwest Oncology Group Trial S0111. J Clin Oncol 2005, 23:8724-8729.
45. Wilding G., Chen Y.-H., DiPaola R., et al. E3803: Updated results on a phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). J Clin Oncol 2008, 26(May 20 Suppl):[Abstract] 5070. (Data updated in ASCO 2008 meeting presentation).
46. Beer T.M., Smith D.C., Hussain A., et al. Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2009, 27(15S). [Abstract] 5059.
47. Rosenberg J.E., Ryan C.J., Weinberg V.K., et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: A study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 2009, 27:2772-2778.
48. Beardsley E.K., Saad F., Eigl B., et al. Phase II study of patupilone in patients (pts) with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. J Clin Oncol 2009, 27(15S). [Abstract] 5139.
49. Hoffmann J., Vitale I., Buchmann B., et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Research 2008, 68:5301-5308.
50. Graff J., Smith D.C., Neerkonch L., et al. Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol 2008, 26(May 20 Suppl):[Abstract] 5141.
51. O'Reilly T., McSheehy P.M., Wenger F., et al. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. Prostate 2005, 65:231-240.
52. Hussain A., Di Paola R.S., Baron A.D., et al. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol (Engl) 2009, 20:492-497.
53. A service of the US National Institutes of Health Clinicaltrials.gov, Accessed January 2009. http://www.clinicaltrials.gov.